This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Marinus Pharmaceuticals’s 8K filing here.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
See Also
- Five stocks we like better than Marinus Pharmaceuticals
- NYSE Stocks Give Investors a Variety of Quality Options
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- How to buy stock: A step-by-step guide for beginners
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Market Overreaction: 2 Stocks to Buy on the Way Down
